Skip to main content
Full access
Communications and Updates
Published Online: 1 January 2012

Overexpression of Chromosome 15q11-q13 Gene Products: A Risk Factor for Schizophrenia and Associated Psychoses?

To the Editor: We read with interest the article by Ingason et al. (1) in the April 2011 issue of the Journal. Their results suggest that the presence of an extra (maternal) copy of a fragment of chromosome 15q11-q13 that overlaps with the Prader-Willi/Angelman syndrome critical region may be a rare risk factor for schizophrenia and other psychoses. We report three cases with the infrequent isodicentric chromosome 15 (idic[15]) syndrome (2), a condition that results in partial tetrasomy 15q and schizophrenia.

Case Reports

“Ms. A” was a 17-year-old woman with mild intellectual disability (IQ=56), recurrent psychotic episodes (incoherence and haptic and auditory hallucinations), and complex partial epilepsy (lip smacking with bilateral EEG abnormalities). Conventional karyotyping and fluorescence in situ hybridization analysis using probes from both proximal chromosome 15 and the Prader-Willi/Angelman syndrome critical region revealed an isodicentric chromosome 15 (47,XX,+idic[15]). Unfortunately, the parental origin of the isochromosome was unknown. After unsuccessful treatment with risperidone (6 mg/day), we administered clozapine (400 mg/day, plasma level=0.096 mg/liter, therapeutic levels=0.20–0.60 mg/liter) and carbamazepine (600 mg/day, plasma level=8.0 mg/liter) with good response.
“Ms. B” and “Ms. C,” 43-year-old apparently monozygotic twins, were both diagnosed with mild intellectual disability (Ms. B's IQ was 63, and IQ was not available for Ms. C) and schizophrenia of disorganized type. Both twins developed their first psychotic symptoms at age 25. Medical records indicated that their mother and father were disabled. Additionally, the father was diagnosed with schizophrenia. Karyotyping and fluorescence in situ hybridization revealed 47,XX,+idic(15). The mother had the same karyotype, while their father's karyotype was a normal 46,XY. Over the years, multiple psychotropic drugs were prescribed with unsatisfactory results in both women. At age 41, Ms. B was treated with clozapine (350 mg/day, plasma level=0.35 mg/liter). Her overall functioning improved substantially, and her psychotic symptoms diminished. Therefore, Ms. C was also switched to clozapine (100 mg/day, plasma level=0.36 mg/liter). Although clinically we observed no significant change in Ms. C, the number of psychotropic drugs in her regimen was reduced from five to one.

Discussion

To our knowledge, these are the first reported cases of both idic(15) syndrome and schizophrenia. These cases provide further support for the supposed association between the 15q11-q13 region and schizophrenia and associated psychoses through the overexpression of (maternal) genes in the region (1). In addition, these cases suggest that clozapine should be considered in treating psychoses associated with idic(15) syndrome.

Footnote

Accepted for publication in October 2011.

References

1.
Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, Möller HJ, McQuillin A, Muglia P, Cichon S, Rietschel M, Ophoff RA, Djurovic S, Andreassen OA, Pietiläinen OP, Peltonen L, Dempster E, Collier DA, St. Clair D, Rasmussen HB, Glenthøj BY, Kiemeney LA, Franke B, Tosato S, Bonetto C, Saemundsen E, Hreidarsson SJ GROUP Investigators, Nöthen MM, Gurling H, O'Donovan MC, Owen MJ, Sigurdsson E, Petursson H, Stefansson H, Rujescu D, Stefansson K, Werge T: Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am J Psychiatry 2011; 168:408–417
2.
Battaglia A, Parrini B, Tancredi R: The behavioral phenotype of the idic(15) syndrome. Am J Med Genet C Semin Med Genet 2010; 154:448–455

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 96 - 97
PubMed: 22223014

History

Accepted: October 2011
Published online: 1 January 2012
Published in print: January 2012

Authors

Affiliations

Erik Boot, M.D., Ph.D.
Amsterdam and Zwammerdam, the Netherlands
Sarina G. Kant, M.D., Ph.D.
Leiden, the Netherlands
Maarten Otter, M.D.
Amersfoort and Zutphen, the Netherlands
Dan Cohen, M.D., Ph.D.
Heerhugowaard and Groningen, the Netherlands
Amal Nabanizadeh, M.D.
Zwammerdam, the Netherlands
Ronald W.J. Baas, M.D.
Zwammerdam, the Netherlands

Funding Information

Dr. Cohen has received unrestricted grants from Eli Lilly and Janssen-Cilag, advisory board fees from AstraZeneca, and speakers fees from AstraZeneca and Bristol-Myers Squibb. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share